(Bloomberg) -- Eli Lilly & Co.’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh the risk of potentially fatal bleeding in the ...
Por THE ASSOCIATED PRESSUna comisión reguladora europea rechazó el tratamiento de Eli Lilly contra la enfermedad de Alzheimer ...
Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...
Eli Lilly’s Alzheimer’s drug Kisunla has failed to get support from the European Medicines Agency over serious side effects ...
Irish Examiner on MSN8h
Eli Lilly fails to get European approval for Alzheimer's drug KisunlaLilly will seek review of decision which said drug's benefits don’t outweigh risk of potentially fatal bleeding in the brain ...
European regulatory committee rejects Lilly's Alzheimer's disease treatment due to potential risks of brain bleeding and ...
A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...
Eli Lilly, which is seeking European approval of Kisunla for the treatment of early symptomatic Alzheimer's, said it will seek re-examination by CHMP. The Indianapolis drugmaker said it remains ...
NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Thursday recommended against marketing authorization for Eli Llilly's Alzheimer's drug Kisunla ...
After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback